Design of a UV-C irradiation process for the inactivation of viruses in protein solutions

Biologicals

Volumn 33, Issue 2, 2005, Pages 101-110

  Li, Qiangyi ^a   MacDonald, Shirley ^a   Bienek, Carol ^a   Foster, Peter R ^a   MacLeod, Alex J ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN;

ARTICLE; CALCULATION; HYDRODYNAMICS; INFORMATION; LIGHT ABSORPTION; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; ULTRAVIOLET IRRADIATION; VIRUS INACTIVATION;

PROTEINS; SOLUTIONS; SPECTROPHOTOMETRY, ULTRAVIOLET; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 20444370296     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biologicals.2005.02.001     Document Type: Article

References (37)

1. W. Werz, H. Hoffmann, K. Haberer, and J.K. Walter Strategies to avoid virus transmission by biopharmaceutical products Arch Virol 13 Suppl. 1997 245 256
2. B. Cuthbertson, K.G. Reid, and P.R. Foster Viral contamination of human plasma and procedures for preventing virus transmission by plasma products J.R. Harris Blood separation and plasma fractionation 1991 Wiley-Liss New York 385 435
3. B. Horowitz, and E. Ben-Hur Efforts in minimising risk of viral transmission through viral inactivation Ann Med 32 2000 475 484
4. P.R. Foster, B. Cuthbertson, R.V. McIntosh, and A.J. MacLeod Safer clotting factor concentrates C.D. Forbes L. Aledort R. Madhok Hemophilia 1997 Chapman and Hall London 307 332
5. H. Willkommen, I. Schmidt, and J. Löwer Safety issues for plasma derivatives and benefit from NAT testing Biologicals 27 1999 325 331
6. J.P. Allain Emerging viruses in blood transfusion Vox Sang 78 Suppl. 2 2000 243 248
7. A. Hollaender Radiation biology vol. 2 1955 McGraw-Hill New York
8. A.D. Russell, W.B. Hugo, and G.A.J. Ayliffe Principles and practice of disinfection, preservation and sterilization third ed. 1999 Blackwell Science Ltd Oxford
9. A.M. Rauth The physical state of viral nucleic acid and the sensitivity of viruses to ultraviolet light Biophys J 5 1965 257 273
10. Y. Watanabe, H. Miyata, and H. Sato Inactivation of laboratory animal RNA-viruses by physicochemical treatment Exp Anim 38 1989 305 311
11. H. Hart, K. Reid, and W. Hart Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin Vox Sang 64 1993 82 88
12. J.W. Oliphant, and A. Hollaender Homologous serum jaundice: experimental inactivation of etiologic agent in serum by ultraviolet irradiation Public Health Rep 61 1946 598 602
13. A.M. Wolf, J. Mason, W.J. Fitzpatrick, S.O. Schwartz, and S.O. Levinson Ultraviolet irradiation of human plasma to control homologous serum jaundice JAMA 135 1947 476 477
14. M.C. Blanchard, J. Stokes, B. Hampil, G.R. Wade, and J. Spizizen Methods of protection against homologous serum hepatitis II. The inactivation of hepatitis virus SH with ultraviolet rays JAMA 138 1948 341 343
15. A.M. Prince, W. Stephan, and B. Brotman β-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives Rev Infect Dis 5 1983 92 107
16. W. Stephan Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with β-propiolactone/UV irradiation J.J. Morgenthaler Virus inactivation in plasma products 1988 Karger Basel
17. N. Rosenthal, F.A. Bassen, and S.R. Michael Probable transmission of viral hepatitis by ultraviolet-irradiated plasma: report of three cases JAMA 144 1950 224 226
18. R. Murray, J.W. Oliphant, J.T. Tripp, B Hampil, F Ratner, and WCL Diefenbach Effect of ultraviolet radiation on the infectivity of icterogenic plasma JAMA 157 1955 8 14
19. J.P. Kleim, E. Bailly, K.E. Schneweis, HH Brackmann, U Hammerstein, and P Hanfland Acute HIV-1 infection in patients with hemophilia treated with beta-propiolactone-UV-inactivated clotting factor Thromb Haemost 64 1990 336 337
20. B. Kupfer, J. Oldenburg, H.H. Brackmann, B Matz, KE Schneweis, and R Kaiser Beta-propiolactone UV inactivated clotting factor concentrate is the source of HIV-infection of 8 hemophilia B patients: confirmed Thromb Haemost 74 1995 1386 1387
21. R. Murray Viral hepatitis Bull N Y Acad Med 31 1955 341 358
22. Committee for Proprietary Medicinal Products. Note for guidance on plasma-derived medicinal products, CPMP/BWP/269/95. European Agency for the Evaluation of Medicinal Products, Rev.2: January 1999.
23. P.R. Foster, and B. Cuthbertson Procedures for the prevention of virus transmission by blood products R. Madhok C.D. Forbes B.L. Evatt Blood, blood products and HIV second ed 1994 Chapman and Hall London 207 248
24. P.W. Atkins Physical chemistry fourth ed. 1996 Oxford University Press Oxford pp. 501-503
25. Kallenbach NR, Cornelius PA, Negus D, Montgomerie D, Englander S. Inactivation of viruses by ultraviolet light. Curr Stud Hematol Blood Transfus 1989;56:122-7. In: Morgenthaler JJ, editor. No 56. Basel: Karger. Curr Stud Hematol Blood Transfus 1989;56:70-82.
26. Gunn A, Cameron I. Body fluid processing device. UK Patent GB2200020; 1988.
27. R.W. Bunsen, and H.E. Roscoe Photochemical researches, part 1. Measurement of the chemical action of light Philos Trans R Soc Lond 147 1857 355 380
28. R.W. Bunsen, and H.E. Roscoe Photochemical researches, part 2. Phenomenon of photochemical induction Philos Trans R Soc Lond 147 1857 381 402
29. Committee for Proprietary Medicinal Products. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses, CPMP/BWP/268/95. European Agency for the Evaluation of Medicinal Products; 1996.
30. R.B. Bird, W.E. Stewart, and E.N. Lightfoot Transport phenomena 1960 John Wiley & Sons New York
31. D.M. Hobbs, and F.J. Muzzio Reynold's number effects on laminar mixing in the Kenics static mixer Chem Eng J 70 2 1998 93 104
32. C. Turnbull, A.G. Welch, N. Docherty, and P.R. Foster A simplified fractionation route for the preparation of human albumin Transfus Med 5 Suppl. 1 1995 41
33. M.H. Adams Bacteriophage 1959 Interscience Publishers Inc New York
34. J. Karber Beitrag zur kollectiven behandlung pharmakologische rehenversuche Arch Exp Pathol Pharmakol 162 1931 480 483
35. Federal Health Office and Paul Erlich Institute Federal Office for Sera and Vaccines. Notice on the registration of drugs: requirements for validation studies to demonstrate the virus safety of drugs derived from human blood or plasma. Bundesanzeiger 1994;84:4742-4.
36. P. Caillet-Fauquet, M. di Giambattista, M.-L. Draps, F Sandras, T Branckaert, and Y de Launoit Continuous-flow UVC irradiation: a new, effective, protein activity-preserving system for inactivating bacteria and viruses, including erythrovirus B19 J Virol Methods 118 2004 131 139
37. J. Wang, A. Mauser, S.-F. Chao, K Remington, R Treckmann, and K Kaiser Virus inactivation and protein recovery in a novel ultraviolet-C reactor Vox Sang 86 2004 230 238